AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
US FDA approval based on NEURO-TTRansform Phase III results
Subscribe To Our Newsletter & Stay Updated